Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by TD Asset Management Inc

Key Points

• TD Asset Management Inc has increased its stake in Halozyme Therapeutics by 5.8%, now holding approximately $92.64 million worth of shares.
• Recent analyst reports have influenced the stock's price targets, with Wells Fargo raising the target from $60.00 to $65.00, while Leerink Partners downgraded it to a "strong sell."
• Halozyme Therapeutics reported $1.11 earnings per share for the last quarter, exceeding estimates and showcasing a 35.2% year-over-year revenue growth.

TD Asset Management Inc grew its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 5.8% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,451,842 shares of the biopharmaceutical company's stock after purchasing an additional 79,708 shares during the quarter. TD Asset Management Inc owned approximately 1.18% of Halozyme Therapeutics worth $92,642,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in HALO. Quantbot Technologies LP boosted its stake in shares of Halozyme Therapeutics by 193.1% during the fourth quarter. Quantbot Technologies LP now owns 7,661 shares of the biopharmaceutical company's stock valued at $366,000 after purchasing an additional 5,047 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $1,253,000. LPL Financial LLC boosted its stake in shares of Halozyme Therapeutics by 36.6% during the fourth quarter. LPL Financial LLC now owns 207,003 shares of the biopharmaceutical company's stock valued at $9,897,000 after purchasing an additional 55,410 shares during the period. Vanguard Group Inc. boosted its stake in shares of Halozyme Therapeutics by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock valued at $634,999,000 after purchasing an additional 386,618 shares during the period. Finally, EntryPoint Capital LLC purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $230,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insider Buying and Selling

In related news, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $56.43, for a total transaction of $1,128,600.00. Following the completion of the transaction, the chief executive officer directly owned 733,719 shares of the company's stock, valued at $41,403,763.17. The trade was a 2.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last ninety days, insiders sold 60,000 shares of company stock worth $3,262,400. Insiders own 2.90% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Leerink Partners lowered Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price target for the company. in a research note on Tuesday, May 13th. The Goldman Sachs Group assumed coverage on Halozyme Therapeutics in a research note on Thursday, July 10th. They issued a "neutral" rating and a $55.00 price target for the company. Morgan Stanley lowered Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and dropped their price target for the stock from $73.00 to $62.00 in a research note on Wednesday, May 14th. JPMorgan Chase & Co. raised their price target on Halozyme Therapeutics from $58.00 to $60.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 16th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, May 29th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of "Hold" and an average price target of $62.70.

Halozyme Therapeutics Trading Up 1.7%

Halozyme Therapeutics stock traded up $1.00 during trading on Wednesday, reaching $60.05. 381,456 shares of the company were exchanged, compared to its average volume of 1,919,135. The stock's 50 day simple moving average is $54.96 and its two-hundred day simple moving average is $57.61. The company has a debt-to-equity ratio of 3.13, a current ratio of 8.39 and a quick ratio of 7.30. The company has a market capitalization of $7.40 billion, a P/E ratio of 15.98, a PEG ratio of 0.39 and a beta of 1.15. Halozyme Therapeutics, Inc. has a 52-week low of $42.01 and a 52-week high of $70.50.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. The company had revenue of $264.86 million during the quarter, compared to analysts' expectations of $231.21 million. During the same quarter last year, the firm earned $0.79 earnings per share. The firm's quarterly revenue was up 35.2% compared to the same quarter last year. On average, equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.